43 results about "Analeptic" patented technology

The present invention provides a proprietary compositions and systems to modulate genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplement formulation to optimize specific health outcomes. Specific to this invention the utilization of certain known polymorphic genes associated with Substance Use Disorder (SUD) are analyzed to target certain genetic anomalies that lead to a high risk and predisposition to SUD. The genotypic patterns are then utilized to provide certain nutritional customized solutions especially related to the attenuation of aberrant abuse of physician prescribed narcotic pain medication across all pain conditions. A priority GENOPROFILE is measured and directs the customization of a subsequent nutraceutical to act as a therapeutic modality. Specifically the treatment includes slow attenuation of the pain medication by incorporating orals (shakes, liquid beverages, pills, tablets, troche, ointments etc.), Intramuscular, Intravenous, intra-rectal and any form necessary to deliver a sufficient amount of an anti-craving and anti-stress nutraceutical. Moreover, the invention includes examples of novel analgesic ointments coupling Synaptamine and such analgesic and other anesthetic compounds including but not limited to Gabapentin, Ketamine, Baclofen, Ketoprofen, Amitriptyline, Lidocaine, Cyclobenzapine, Diclofenac, Menthol, Camphor and Capsaicin. The GENOPROFILE will be used to determine pain sensitivity Intolerance.

The present invention pertains to a pharmaceutical dosage form comprising an opioid analgesic and a nontoxic N-methyl-D-aspartate receptor antagonist wherein the pharmaceutical dosage form is substantially free of an opioid antagonist The nontoxic N-methyl-D-aspartate receptor antagonist is present in an opioid euphoria-inhibiting amount to prevent or discourage abuse.

The invention relates to a venin-sourced demulcent CTXn, and a purification method and applications thereof. The invention is characterized in that (1) the molecular weight of the CTXn is 6697.429 Da; (2) and the amino acid sequence of the CTXn is described as the sequence list SEQ ID No.1. The preparation method comprises the following steps of: using a Zhoushan cobra venom sample; carrying out the CTXn separation and purification on the Zhoushan cobra venom sample; primary-screening to select a component III for next step of ion exchange; carrying out the ion exchange on the component III through a quick-purification technique exploitation system by using a filler to obtain a single-virulence polypeptide CTXn, desalting with a G-50 prepacked column, and freeze-drying; and measuring the molecular weight and the amino acid sequence of the CTXn. The CTXn of the invention has favorable demulcent function on somatalgia and visceralgia caused by nociceptive stimulus as well as pains caused by addiction to morphine, has the characteristics of obvious drug effect and low toxic or side effect, is beneficial to large-scale production, and has wide application prospects in the aspect of analgesic development.

The present invention relates to methods of alleviating pain with the administration of norketamine with a narcotic. More particularly, the invention provides a method of alleviating pain through the administration of a dose of norketamine, which, if administered alone would provide sub-optimal analgesic relief, yet provides analgesic relief when combined with a narcotic. In some embodiments, the combination of norketamine with a narcotic, further allows for the administration of a dose narcotic, which would be sub-optimal if used alone, but provides adequate pain relief in combination with norketamine. The invention relates to self-management of pain on an outpatient basis comprising administering via conventional routes, including transdermal, nasal, rectal, oral, transmucosal, intravenous, intramuscular, and other routes, one or more doses of norketamine/opioid compositions effective to alleviate pain to a subject suffering from pain. Uses of norketamine/opioid compositions would also apply, to treating headaches, drug abuse, mood and anxiety disorders, as well as other, neuropsychiatric disorders, both motoric and cognitive, such as Alzheimer's disease, Parkinson's syndrome, which are thought to be caused by neurodegeneration.

Capsule preparations are produced by using solutions for capsule-filling which contain ibuprofen, polyethylene glycol, water and terpenes (menthol, limonene, borneol, dl-camphor, mentha oil, etc.) optionally together with one or more drugs selected from among antipyretic analgesics, antihistamines, antitussives, expectorants, sympathetic stimulant, analeptics, hypnotic sedatives and anti-inflammatory agents, solubilizers, thickeners, pH controlling agents, colorants, etc. Thus, it is attempted to relieve the bitterness of ibuprofen and establish an immediate action at the same time.

A slowly-releasing tablet of analgesic rotundine is disclosed.

The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.

The invention features combinations of dopaminergic agents and analgesic agents useful for treating pain. In particular, the combinations feature a low ratio of dopaminergic agent to analgesic agent. The dopaminergic agent can be an agonist of the dopamine receptor D1-like family or the dopamine receptor D2-like family. Such combinations potentiate analgesia to 1) alleviate acute pain, 2) prevent the transition from acute pain to chronic pain, and 3) manage chronic pain.

This invention relates to a drug containing edible acid and/or acidic salt as active agent to treat and alleviate hypersensitivity diseases by lowering the humor pH and method; to improve individual hypersensitivity diseases by uses of health care food, which are made from said edible acid and/or acidic salt, or the acidic fruits containing thereof, or their products; foods lowering the risk of hypersensitivity and their preparation methods; drug to lower the humor acidity and to treat or alleviate disease caused by insects bite toxin; that also to be drug for cold or virus infection; drug for inflammation; drug for analgesic; and drug for thrombus disease; method lowers the hypersensitivity risk of clothing or grove and their products.

The invention belongs to the field of the medicines for animals and discloses a painless synergistic amoxicillin powder injection for animals and a preparation method thereof. The powder injection comprises the following components in parts by weight: 48-52 parts of amoxicillin or amoxicillin sodium (active ingredient), 10-30 parts of a cosolvent, 1-3 parts of an analgetic, 5-8 parts of probenecid sodium and 1-2 parts of an antifebrile anti-inflammatory analgesic. The preparation method of the powder injection comprises the following steps of: in parts by weight, evenly mixing 1-3 parts of analgetic, 5-8 parts of probenecid sodium and 1-2 parts of antifebrile anti-inflammatory analgesic together, and then evenly mixing the mixture with 48-52 parts of amoxicillin or amoxicillin sodium (active ingredient) and 10-30 parts of cosolvent, thereby obtaining the painless synergistic amoxicillin powder injection. The amoxicillin powder injection prepared by the preparation method provided by the invention solves the problems of strong injection pricking stress, poor effects of anti-inflammation and analgesia, and heat elimination and defervescence, ingestion reduction after the administration of the drug, and the like; and the product is highly required in clinical application, and is wide in market prospect and huge in social benefit.

A method for treatment of dependence and dependence related withdrawal symptoms caused by the discontinuation of subacute or chronic use of psychostimulant agents, to ease a patient's withdrawal from the psychostimulants with an alpha2-adrenoceptor antagonist or a pharmaceutically acceptable ester or salt thereof.

The invention relates to a following formula I showed compound in a free form, a salt form or a solvated form and having a beta2-receptor exciting effect. II and III are contained in R1, Ar are following formula groups IV and V, definition of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R13, R14, R15, R16, m and o is shown in the description. The invention further relates to a preparation method of the compound and application of a compound serving as a drug, in particular to treatment of diseases such as a chronic obstructive pulmonary disease, asthma and heart failure the aspects of a respiratory and cardiovascular system and a cardiovascular system.

A peptide with the following sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or a derivative thereof, and nucleic acids coding for the peptide having the sequence (SEQ ID NO 1). Also the use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels. A use of the peptide for preparing a drug, in particular an analgesic one.

The use of opioid peptides of a novel structure is claimed which, in addition to a pharmacophore, additionally contain structural elements reactive with tachykinin receptors. Due to the synergistic reactivity of the opioid with an additional element, an increased analgesic activity is obtained facilitating protracted effective use due to decreased drug tolerance effects. The drugs may particularly be of use in the treatment of chronic pain as effective analgesics during inflammation caused by rheumatism, gout, neurodegenerative states, post-surgical and post-traumatic inflammations or ones induced by tumours.

Methods of preventing the development and reversing or partially reversing opioid tolerance in a subject are provided herein. Such methods include the step of administering to a subject in need thereof a therapeutically effective amount of a PDGFR modulator or EGFR modulator alone or together with an opiate analgesic. The methods can also be used for the treatment of refractory neuropathic pain, physical dependence or addiction.

A device (154) for sensing sweat on skin (12) includes an analyte-specific sensor (166, 168) for sensing an analyte in sweat; a sweat stimulant reservoir (174, 176, 178) separated from a waste water reservoir (184) by a water-permeable, sweat-stimulant impermeable membrane (182). The waste water reservoir (184) has a wicking force that is not greater than the wicking force of the sweat stimulant reservoir (174, 176, 178). The waste water reservoir (184) removes excess water from sweat to prevent the dilution of the sweat stimulant from the sweat stimulant reservoir (174, 176, 178), thereby maintaining the effectiveness of the sweat stimulant.